摘要
Objective: To analyze the effect of Danshen polyphenols combined with doxofylline treatment in patients with chronic pulmonary heart disease in the compensated stage. Methods: 76 patients with chronic pulmonary heart disease in the compensated stage were selected from January 2023 to January 2024 as the study subjects, and they were divided into a study group and a reference group through a random number table. the study group was treated with Danshen polyphenols combined with doxorubicin while the reference group was treated with conventional treatment, and the treatment effects of the two groups were compared. Results: The patients in the study group were treated with Danshen polyphenols combined with doxorubicin, and the maximal ventilation was 73.26 ± 4.83 L/min, the left ventricular ejection fraction was 56.14 ± 1.98 %, and the total effective rate of the treatment was 94.74%, which were all significantly better than those of the reference group (P < 0.05), which is statistically significant. Conclusion: Danshen polyphenols combined with doxofylline treatment resulted in an improvement in maximum ventilation and left ventricular ejection fraction, and its overall efficacy is also higher than conventional treatment in treating chronic pulmonary heart disease in the compensated stage.
参考
Wang B, Liang F, 2024, Analysis of the Clinical Diagnostic Value of Amino-Terminal Brain Natriuretic Peptide Precursor and Troponin T Detection in Patients with Chronic Pulmonary Heart Disease in the Compensatory Stage. Medical Theory and Practice, 37(04): 650–652.
Bao Z, Shen C, Wang W, 2024, Study on the Efficacy of Dagliflozin in the Treatment of Patients with Right Heart Failure in the Compensated Stage of Chronic Pulmonary Heart Disease. Clinical Medicine Practice, 33(01): 18–21.
Wang T, Ren X, Gong W, et al., 2023, Evaluation of Cardiac Function, Structure and Myocardial Changes in Patients with Chronic Pulmonary Heart Disease in the Compensated Stage by Magnetic Resonance Mapping Technique. Imaging Research and Medical Applications, 7(18): 89–91.
Wang H, 2023, Effect of Ivabradine Treatment on Cardiopulmonary Function and Inflammatory Indexes in Patients with Chronic Pulmonary Heart Disease in Compensated Stage with Heart Failure[J]. Heilongjiang Medicine, 47(09): 1072–1074.
Nurmameti R, 2022, Clinical Characteristics and Therapeutic Analysis of Patients with Chronic Pulmonary Heart Disease Combined with Coronary Heart Disease in the Compensated Stage. Electronic Journal of Integrated Cardiovascular Disease of Chinese and Western Medicine, 10(33): 21–23 + 11.
Yu S, 2023, Clinical Effect Analysis of Conventional Therapy Combined with Nitrate Drugs in the Treatment of Chronic Pulmonary Heart Disease Combined with Coronary Heart Disease. Chinese Community Physician, 39(26): 50–52.
Wang Y, Yan F, 2022, Clinical Effect of Milrinone Combined with Qi Shen Yi Qi Drip Pill in the Treatment of Chronic Pulmonary Heart Disease. Qinghai Medical Journal, 52(12): 12–14.
Chen F, Li Z, 2023, Efficacy and Safety of Tanshinone Injection Combined with Fasudil in the Treatment of Chronic Pulmonary Heart Disease in the Elderly. Journal of Chronic Disease, 2023(2): 308–311.
Tang Y, Hu Y, Li D, et al., 2022, Clinical effect of Danshen Injection Combined with Cyclophosphoadenosine Glucosamine in the Treatment of Pulmonary Heart Disease. Journal of Clinical Rational Drug Use, 15(20): 52–54 + 58.
Wang Z, Chen X, Xu Y, 2022, Clinical Study of Shenmai Injection Combined with Trimetazidine in the Treatment of Chronic Pulmonary Heart Disease Combined with Respiratory Failure in the Elderly. New Chinese Medicine, 54(18): 40–44.